Toremifene, a novel antiestrogen, can overcome hsp27-induced drug resistance in human breast cancer cells

David M. Mahvi, Stephen W. Carper*, Conrad O. Yu, Teresa A. McCausland, F. Kristian Storm

*Corresponding author for this work

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Human breast cancer cell lines derived from MDA-MB-231 were constructed to express hsp27 constitutively. The elevated presence of this protein resulted in an enhanced ability to survive a heat shock and exposure to doxorubicin, a chemotherapeutic agent. Hsp217 expression was unable to protect cells from doxorubicin if they were cultured in the presence of toremifene. Flow cytometry analysis indicated that cells exposed to both toremifene and doxorubicin accumulate at G2 + M. Protective effects of hsp27 were overcome by addition of an estrogen antagonist at clinically nontoxic levels. Addition of toremifene to chemotherapeutic regimes may enhance the sensitivity of breast cancer cells to doxorubicin.

Original languageEnglish (US)
Pages (from-to)269-275
Number of pages7
JournalEndocrine
Volume4
Issue number3
DOIs
StatePublished - Jun 1996

Keywords

  • Breast cancer
  • Chemotherapy
  • Heat shock protein
  • Toremifene
  • hsp27

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Toremifene, a novel antiestrogen, can overcome hsp27-induced drug resistance in human breast cancer cells'. Together they form a unique fingerprint.

  • Cite this

    Mahvi, D. M., Carper, S. W., Yu, C. O., McCausland, T. A., & Kristian Storm, F. (1996). Toremifene, a novel antiestrogen, can overcome hsp27-induced drug resistance in human breast cancer cells. Endocrine, 4(3), 269-275. https://doi.org/10.1007/bf02738693